###begin article-title 0
###xml 38 41 38 41 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 70 74 <span type="species:ncbi:10090">Mice</span>
Short and Long-Term Effects of hVEGF-A165 in Cre-Activated Transgenic Mice
###end article-title 0
###begin p 1
Conceived and designed the experiments: SY PL KA JJ. Performed the experiments: IK AM SK HM JN. Analyzed the data: SY PL IK AM JN. Contributed reagents/materials/analysis tools: KA MW LA. Wrote the paper: SY PL IK AM KA
###end p 1
###begin p 2
###xml 50 53 50 53 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 162 165 162 165 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 337 340 337 340 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 425 428 425 428 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 659 662 659 662 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 720 723 720 723 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 1060 1063 1060 1063 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 1359 1362 1359 1362 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 31 36 <span type="species:ncbi:10090">mouse</span>
###xml 185 189 <span type="species:ncbi:10090">mice</span>
###xml 402 406 <span type="species:ncbi:10090">mice</span>
###xml 563 567 <span type="species:ncbi:10090">mice</span>
###xml 688 693 <span type="species:ncbi:10090">mouse</span>
###xml 892 896 <span type="species:ncbi:10090">mice</span>
###xml 1007 1011 <span type="species:ncbi:10090">mice</span>
###xml 1125 1129 <span type="species:ncbi:10090">mice</span>
We have generated a transgenic mouse where hVEGF-A165 expression has been silenced with loxP-STOP fragment, and we used this model to study the effects of hVEGF-A165 over-expression in mice after systemic adenovirus mediated Cre-gene transfer. Unlike previous conventional transgenic models, this model leads to the expression of hVEGF-A165 in only a low number of cells in the target tissues in adult mice. Levels of hVEGF-A165 expression were moderate and morphological changes were found mainly in the liver, showing typical signs of active angiogenesis. Most mice were healthy without any major consequences up to 18 months after the activation of hVEGF-A165 expression. However, one mouse with a high plasma hVEGF-A165 level died spontaneously because of bleeding into abdominal cavity and having liver hemangioma, haemorrhagic paratubarian cystic lesions and spleen peliosis. Also, two mice developed malignant tumors (hepatocellular carcinoma and lung adenocarcinoma), which were not seen in control mice. We conclude that long-term uncontrolled hVEGF-A165 expression in only a limited number of target cells in adult mice can be associated with pathological changes, including possible formation of malignant tumors and uncontrolled bleeding in target tissues. These findings have implications for the design of long-term clinical trials using hVEGF-A165 gene and protein.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 181 184 181 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000013-Maglione1">[1]</xref>
###xml 186 189 186 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000013-Joukov1">[2]</xref>
###xml 455 458 455 458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000013-Ferrara1">[3]</xref>
###xml 460 463 460 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000013-YlHerttuala1">[4]</xref>
Vascular endothelial growth factor (VEGF-A) was the first identified member of the family that now includes placental growth factor (PIGF) and several other VEGFs (VEGF-B,-C,-D,-E) [1], [2]. Since then the VEGF family has been shown to play a major role in vascular permeability, angiogenesis and lymphangiogenesis both during embryonic development and in adults. VEGFs have also been used in clinical applications as recombinant proteins or gene therapy [3], [4]. However, long term effects of moderate VEGF over-expression in adults have not been characterized in the context of recombinant protein or gene therapy.
###end p 4
###begin p 5
###xml 209 212 209 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000013-Ferrara2">[5]</xref>
###xml 213 216 213 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000013-Gerber1">[7]</xref>
###xml 251 254 251 254 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">120</sub>
###xml 342 345 342 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000013-Carmeliet2">[8]</xref>
###xml 671 675 671 675 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000013-Bellomo1">[11]</xref>
###xml 676 680 676 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000013-Baldwin1">[13]</xref>
###xml 882 886 882 886 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000013-Vogel1">[14]</xref>
###xml 887 891 887 891 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000013-Dor1">[18]</xref>
###xml 940 944 940 944 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000013-Odorisio1">[19]</xref>
###xml 1285 1289 1285 1289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000013-Jeltsch1">[20]</xref>
###xml 1290 1294 1290 1294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000013-Mandriota1">[22]</xref>
###xml 1545 1549 1545 1549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000013-Laitinen1">[23]</xref>
###xml 1551 1555 1551 1555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000013-Puumalainen1">[24]</xref>
###xml 181 185 <span type="species:ncbi:10090">mice</span>
###xml 224 228 <span type="species:ncbi:10090">mice</span>
###xml 363 367 <span type="species:ncbi:10090">mice</span>
###xml 426 430 <span type="species:ncbi:10090">mice</span>
###xml 533 537 <span type="species:ncbi:10090">mice</span>
###xml 572 576 <span type="species:ncbi:10090">mice</span>
###xml 625 629 <span type="species:ncbi:10090">mice</span>
###xml 701 706 <span type="species:ncbi:10090">mouse</span>
###xml 904 919 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1017 1021 <span type="species:ncbi:10090">mice</span>
###xml 1106 1121 <span type="species:ncbi:10090">transgenic mice</span>
Due to the fundamental requirement of VEGF-A in embryonal development it has been impossible to create viable knockout models for VEGF-A. Even by knockout of a single VEGF-A allele mice were unable to survive [5]-[7]. Also, mice expressing only VEGF-A120 but no longer isoforms die within two weeks after birth because of the cardiac failure [8]. VEGF-C knockout mice die due to the lack of lymphatic vessels, while VEGF-C+/- mice survive despite of the defects in lymphatic vessels [9.10]. In contrast to VEGF-A and VEGF-C knockout mice VEGF-B, VEGF-D and PIGF deficient mice are viable, and PIGF and VEGF-B double-knockout mice showed no significant vascular phenotype [11]-[13]. Several transgenic mouse models have been generated using the members of the VEGF family. Transgenic VEGF-A has been expressed in the skin, eyes, lungs, heart or liver under tissue specific promoters [14]-[18]. Also, PIGF transgenic mice have been described [19]. Similar results have been reported from these models, showing that all mice have increased vascularization and vascular permeability. In contrast, studies with transgenic mice over-expressing VEGF-C and VEGF-D under keratinocyte or pancreas specific promoters have demonstrated the role of these growth factors mainly in lymphangiogenesis [20]-[22]. However, in all these models VEGFs are typically expressed in every cell of the target tissue and the models may not fully predict outcome after gene therapy applications where transduction efficiency is typically <1-5% of the cells in target organ [23], [24].
###end p 5
###begin p 6
###xml 99 102 99 102 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 207 211 207 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000013-Kilby1">[25]</xref>
###xml 351 354 351 354 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 643 647 640 644 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000013-Laitinen1">[23]</xref>
###xml 649 653 646 650 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000013-Leppnen1">[26]</xref>
###xml 753 756 750 753 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 935 938 932 935 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 1057 1061 1054 1058 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000013-Hiltunen1">[27]</xref>
###xml 1063 1067 1060 1064 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000013-YlHerttuala2">[28]</xref>
###xml 31 36 <span type="species:ncbi:10090">mouse</span>
###xml 577 580 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 614 621 <span type="species:ncbi:9031">chicken</span>
###xml 694 699 <span type="species:ncbi:10090">mouse</span>
We have generated a transgenic mouse model containing in its genome a loxP-STOP inactivated hVEGF-A165 expression cassette, which can be activated by Cre gene transfer in any tissue at any point during life [25]. The main reason for the generation of the current transgenic model was to evaluate potential long-term side effects of therapeutic hVEGF-A165 gene transfer. In this construct we have used the same type of enhancer as we have used in our previous gene transfer studies, but employed a more methylation-resistant promoter in order to achieve a long-term expression (CMV immediate early enhancer and the chicken beta-actin promoter) [23], [26]. In the present study we have used this mouse model to study short and long-term effects of hVEGF-A165 over-expression on the pathology of liver and various other tissues. Systemic AdCre gene transfer was chosen for the study since this leads primarily to the activation of hVEGF-A165 in the liver, which is the most common site of unintended biodistribution of adenoviruses after in vivo gene transfer [27], [28].
###end p 6
###begin title 7
Results and Discussion
###end title 7
###begin title 8
###xml 22 25 22 25 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
Testing of the hVEGF-A165 expression cassette and Short-term effects
###end title 8
###begin p 9
###xml 53 61 53 61 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000013-g001">Figure 1</xref>
###xml 145 148 145 148 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 259 262 259 262 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 380 383 380 383 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 471 474 471 474 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 534 537 534 537 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 760 768 760 768 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000013-g002">Figure 2</xref>
###xml 773 781 773 781 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0000013-t001">Table 1A</xref>
###xml 830 833 830 833 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 1043 1046 1043 1046 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
###xml 1058 1061 1058 1061 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 1126 1134 1126 1134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000013-g002">Figure 2</xref>
###xml 1377 1380 1377 1380 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 1571 1574 1571 1574 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 1791 1795 1791 1795 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000013-Dor1">[18]</xref>
###xml 1851 1854 1851 1854 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 1914 1917 1914 1917 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
###xml 1952 1955 1952 1955 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 2071 2074 2059 2062 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 2074 2078 2062 2066 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000013-Leppnen1">[26]</xref>
###xml 2107 2116 2095 2104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000013-g003">Figure 3A</xref>
###xml 2131 2134 2119 2122 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 2519 2534 2507 2522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000013-g003">Figure 3B and C</xref>
###xml 2696 2699 2681 2684 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 2773 2773 2758 2758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0000013-t001"/>
###xml 2773 2780 2758 2765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0000013-t001">Table 1</xref>
###xml 2794 2803 2779 2788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000013-g003">Figure 3D</xref>
###xml 16 31 <span type="species:ncbi:10090">transgenic mice</span>
###xml 384 399 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1020 1025 <span type="species:ncbi:10090">mouse</span>
###xml 1109 1124 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1195 1210 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1226 1230 <span type="species:ncbi:10090">mice</span>
###xml 1275 1290 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1425 1440 <span type="species:ncbi:10090">transgenic mice</span>
###xml 2425 2429 <span type="species:ncbi:10090">mice</span>
###xml 2609 2616 <span type="species:ncbi:9031">chicken</span>
Before creating transgenic mice the pFlox construct (Figure 1) was tested in vitro and the cassette was found functional causing a strong hVEGF-A165 expression after AdCre-mediated excision of the STOP fragment. AdCre and pFlox treated cells expressed hVEGF-A165 efficiently reaching the peak expression at 24 h after the transduction. Cells transduced with pFlox alone or hVEGF-A165 transgenic mice without gene transfer did not express any detectable amounts of hVEGF-A165 during the follow-up time. The functionality of the hVEGF-A165 transgene in vivo was verified by MRI, where typical changes were seen as discrete edema localized under the skin in all transduced muscles and their fascia and also in the fat tissue due to increased vessel permeability (Figure 2 and Table 1A). We used ELISA to measure the levels of hVEGF-A165 in order to see total protein levels of the transgene both in sera and tissues. The possible gross-reactivity was tested after local gene transfer and no correlations were found between mouse endogenous VEGF-A164 and hVEGF-A165 levels in the control and the AdCre transduced transgenic mice (Figure 2). Systemic AdCre gene transfer via tail vein was done to 31 transgenic mice and 10 control mice at the age of 2 months. Also, 10 additional transgenic mice were injected with saline or AdLacZ. One week after activation a wide range of hVEGF-A165 concentrations were detected in sera of the transgenic mice. We estimate that only 0.1 to 5% of all cells in the liver were transduced after the AdCre gene transfer and the levels of hVEGF-A165 were only moderate in comparison to the transgene expression levels achieved in tissues in previously generated transgenic VEGF-A models where all cells in a given tissue express the transgene. For example Dor et al [18] were able to achieve 7- to 11-fold increases in hVEGF-A165 expression as compared with the level of endogenous mVEGF-A164 After 1 week the levels of hVEGF-A165 in serum were approximately50% of the levels achieved after direct gene transfer with adenoviruses encoding hVEGF-A165[26]. During the next 3-4 weeks (Figure 3A) serum hVEGF-A165 levels decreased. This could be due to the immune response against adenovirus or toxicity of Cre, even if no signs of pathological responses were found in clinical chemistry or histological sections; apoptotic cells were present in all livers transduced with AdCre, but also in the control mice (data not shown) and no major abnormalities were seen (ASAT and CRP) between the groups (Figure 3B and C). The promoter area was selected to be more resistant to methylation (the chicken beta-actin promoter) and in contrast to serum levels, low expression of hVEGF-A165 was present in many tissues even after 18 months as analyzed with ELISA (Table 1) and RT-PCR (Figure 3D).
###end p 9
###begin p 10
###xml 121 125 121 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000013-Hiltunen1">[27]</xref>
###xml 174 177 174 177 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 292 292 292 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0000013-t001"/>
###xml 292 299 292 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0000013-t002">Table 1</xref>
###xml 448 451 448 451 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 507 510 507 510 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
###xml 544 547 544 547 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 740 751 740 751 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000013-g004">Figure 4A&#8211;C</xref>
###xml 945 954 945 954 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000013-g004">Figure 4C</xref>
###xml 1098 1101 1098 1101 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 1103 1112 1103 1112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000013-g004">Figure 4D</xref>
###xml 1186 1189 1186 1189 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 1203 1207 1203 1207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000013-Dor1">[18]</xref>
###xml 1209 1213 1209 1213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000013-Belteki1">[29]</xref>
###xml 1214 1218 1214 1218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000013-LeCouter1">[30]</xref>
###xml 238 242 <span type="species:ncbi:10090">mice</span>
###xml 345 350 <span type="species:ncbi:9606">human</span>
###xml 355 360 <span type="species:ncbi:10090">mouse</span>
###xml 1149 1164 <span type="species:ncbi:10090">transgenic mice</span>
Adenoviral gene expression after systemic gene transfer is typically seen in the liver, heart, kidneys, spleen and lungs [27]. Accordingly, changes in histology after hVEGF-A165 expression were seen in the liver, heart and spleen in most mice, but usually not in the lungs or in the kidneys (Table 1). This can be explained by comparison of the human and mouse endogenous VEGF-A protein levels in different tissues. In the lungs the maximal hVEGF-A165 protein expression levels were only 2-8% of the mVEGF-A164 levels and in the kidneys hVEGF-A165 protein expression rapidly decreased to low or undetectable levels. At the early time points, 1-4 weeks after the AdCre gene transfer, histopathological changes were found only in the livers (Figure 4A-C). An increased number of capillaries featured active angiogenesis: formation of glomeruloid bodies, increased sprouting and branching, sac-like structures and focal hemangioma-like structures (Figure 4C). The number of capillaries correlated with the number of proliferating hepatocytes (PCNA positive nuclei) and the expression levels of hVEGF-A165 (Figure 4D). Similar results have been seen in transgenic mice which express hVEGF-A165 in the liver [18], [29]-[30].
###end p 10
###begin title 11
###xml 28 31 28 31 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
Long-terms effect of hVEGF-A165
###end title 11
###begin p 12
###xml 216 225 216 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000013-g005">Figure 5A</xref>
###xml 502 511 498 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000013-g005">Figure 5B</xref>
###xml 602 614 598 610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000013-g005">Figure 5C, E</xref>
###xml 650 653 646 649 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 690 694 686 690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000013-Hiltunen2">[31]</xref>
###xml 753 762 749 758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000013-g005">Figure 5F</xref>
###xml 955 966 951 962 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000013-g005">Figure 5G&#8211;J</xref>
###xml 232 236 <span type="species:ncbi:10090">mice</span>
###xml 341 345 <span type="species:ncbi:10090">mice</span>
###xml 383 388 <span type="species:ncbi:10090">mouse</span>
###xml 559 563 <span type="species:ncbi:10090">mice</span>
###xml 703 708 <span type="species:ncbi:10090">mouse</span>
###xml 777 782 <span type="species:ncbi:10090">mouse</span>
###xml 924 929 <span type="species:ncbi:10090">mouse</span>
Within 6-18 months after the AdCre gene transfer increased vascularization and proliferation of hepatocytes persisted in the livers, but morphological abnormalities and signs of active angiogenesis were less common (Figure 5A). All mice were healthy without any major consequences up to 13 months and only minor changes were seen: Out of 19 mice in the long-term follow-up group one mouse had a hepatic focal basophilic hyperplasia of 500 microm in diameter containing cells with a high amount of fat (Figure 5B). In heart, we found discrete edema and in two mice epicardial calcification was present (Figure 5C, E), which can be explained by hVEGF-A165 capacity to increase bone formation [31]. In one mouse the fallopian tube was highly vascularized (Figure 5F) and in other mouse increased vascularization, occasional focal fibrosis and paraductal lymphocytic infiltration was found in pancreas. Also, testis of the same mouse was highly vascularized (Figure 5G-J). No changes were found in ovaries and kidneys. Generally, all angiogenic changes were found at the level of capillaries and arterioles/venules and featured increased number of vessels, enlargement of vessels and local angiogenic activity.
###end p 12
###begin p 13
###xml 204 216 204 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000013-g006">Figure 6A, B</xref>
###xml 279 282 279 282 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 472 476 472 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000013-Frith1">[32]</xref>
###xml 522 525 522 525 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 582 585 582 585 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
###xml 626 629 626 629 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 685 688 685 688 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 1094 1097 1094 1097 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 1231 1234 1231 1234 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 1332 1343 1332 1343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000013-g006">Figure 6C&#8211;E</xref>
###xml 1473 1476 1473 1476 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 1495 1506 1495 1506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000013-g006">Figure 6F&#8211;H</xref>
###xml 1743 1754 1743 1754 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000013-g006">Figure 6I&#8211;K</xref>
###xml 1852 1855 1852 1855 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 1958 1969 1958 1969 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000013-g006">Figure 6L&#8211;N</xref>
###xml 2048 2051 2048 2051 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 91 96 <span type="species:ncbi:10090">mouse</span>
###xml 233 237 <span type="species:ncbi:10090">mice</span>
###xml 405 410 <span type="species:ncbi:10090">mouse</span>
###xml 444 448 <span type="species:ncbi:10090">mice</span>
###xml 559 564 <span type="species:ncbi:10090">mouse</span>
###xml 876 891 <span type="species:ncbi:10090">transgenic mice</span>
###xml 933 937 <span type="species:ncbi:10090">mice</span>
###xml 985 1000 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1109 1114 <span type="species:ncbi:10090">mouse</span>
###xml 1325 1330 <span type="species:ncbi:10090">mouse</span>
At the eighteen months follow-up after the gene transfer major consequences were seen; one mouse developed a hepatocellular carcinoma in the liver and another had a papillary adenocarcinoma in the lungs (Figure 6A, B). Both of these mice had moderate expression levels of hVEGF-A165 in serum after 1 week (240 and 710 pg/ml). We and others have previously seen spontaneous carcinomas in the liver in many mouse models, especially in old female mice with balb/C background [32] and also the transgenic expression of hVEGF-A165 especially in the lungs was low (mouse endogenous VEGF-A164 levels were 25 times higher than hVEGF-A165). Still, we cannot exclude the possibility that hVEGF-A165 played a role in the formation of tumors by inducing the growth of dormant tumors or by some other mechanism, especially in the case of hepatocellular carcinoma. In contrast of activated transgenic mice only benign tumors were found in control mice with the same age (wt with Ad gene transfer or transgenic mice without activation); a thecoma in the fallopian tube and an adenoma in the lungs. One hVEGF-A165 transgenic mouse died spontaneously 16 months after the gene transfer with abdominal cavity full of blood and serum levels of hVEGF-A165 still over 500 pg/ml. Many changes were seen macroscopically in different tissues of this mouse (Figure 6C-E). Microscopically a pendulating cavernous hemangioma (7 millimetres in diameter) was present in the liver with weak focal hVEGF-A165 immunoreactivity (Figure 6F-H). Also, the spleen showed a combination of fibrous scars, which were reminiscent of Gandy-Gamna nodules described as a consequence of focal haemorrhage and dilated cystic spaces which were focally filled with blood resembling peliosis (Figure 6I-K). In the same animal the whole paratubary area was highly vascularized and revealed focal hVEGF-A165 positivity with signs of old haemorrhage and thrombus formation in dilated cystic paratubary spaces. (Figure 6L-N). All of these findings can be connected with local over-expression of hVEGF-A165.
###end p 13
###begin p 14
###xml 84 87 84 87 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 217 220 217 220 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 332 335 332 335 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 891 894 891 894 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 1106 1109 1106 1109 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 44 49 <span type="species:ncbi:10090">mouse</span>
###xml 291 295 <span type="species:ncbi:10090">mice</span>
###xml 492 496 <span type="species:ncbi:10090">mice</span>
###xml 571 576 <span type="species:ncbi:10090">mouse</span>
###xml 739 743 <span type="species:ncbi:10090">mice</span>
In conclusion, we have created a transgenic mouse model which over-expresses hVEGF-A165 after Cre-protein gene transfer. By using different vectors, tissue specific promoters and local gene transfer techniques hVEGF-A165 expression can be targeted in desired tissues and cell types in adult mice. In this model the levels of hVEGF-A165 expression were moderate and typical angiogenetic changes were mostly found in the liver, but also in some other tissues after systemic gene transfer. Most mice were healthy without any major consequences up to 18 months. However, one mouse died spontaneously because of bleeding into abdominal cavity and having liver hemangioma, haemorrhagic paratubarian cystic lesions and spleen peliosis. Also, two mice developed malignant tumors (hepatocellular carcinoma and lung adenocarcinoma). Thus, we concluded that uncontrolled long-term expression of hVEGF-A165 may cause significant pathological changes in target tissues and tight regulation of the transgene expression seems to be a prerequisite for all therapeutic applications aiming at long-term expression of hVEGF-A165.
###end p 14
###begin title 15
Methods
###end title 15
###begin title 16
###xml 45 48 45 48 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 33 38 <span type="species:ncbi:9606">human</span>
Generation of the Cre controlled human VEGF-A165 expression cassette
###end title 16
###begin p 17
###xml 707 711 701 705 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000013-Lakso1">[33]</xref>
###xml 875 878 869 872 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 930 933 924 927 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 978 986 972 980 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000013-g001">Figure 1</xref>
###xml 249 252 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 286 293 <span type="species:ncbi:9031">chicken</span>
###xml 319 325 <span type="species:ncbi:9986">rabbit</span>
###xml 647 651 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
###xml 1088 1091 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 1215 1220 <span type="species:ncbi:9606">human</span>
An oligonucleotide containing restriction sites for Xho I and Sda I was cloned into a Bgl II+Dra II-digested pcDNA3 vector (Invitrogen). The resulting plasmid was named pcDNAmcs. A Sal I and Pst I fragment containing CAG promoter (consisting of the CMV immediate early enhancer and the chicken beta-actin promoter) and rabbit beta-globin polyA from pCAGGS plasmid (a generious gift from Prof. Jun-ichi Miyazaki) was cloned into XhoI/SdaI cut pcDNAmcs. A loxP site containing an MCS oligo linker was cloned into the EcoRI site of the plasmid. The resulting plasmid was named pCaGGSmcs. A BamHI digested and blunted STOP-cassette (consisting of the SV40 early polyadenylation signal and a splice donor signal [33] from the pBS302 (RIKEN DNA Bank) was incorporated into Pml I site of the pCAGGSmcs. The resulted plasmid was digested with EcoRI and EcoRV and ligated with hVEGF-A165 cDNA (digested by EcoRI and EcoRV from pCMV-hVEGF-A165). The resulting plasmid was named as pFlox (Figure 1) and first tested in NIH-3T3 cells which were tranduced by Cre adenovirus (containing Cre gene under CMV promoter) at MOI 500. 12 h after transduction, cells were transduced with the pFlox plasmid. Medium samples were taken for human VEGF-A ELISA analysis (R&D Systems, Minneapolis, USA) at different time points.
###end p 17
###begin title 18
Experimental animals
###end title 18
###begin p 19
###xml 226 229 226 229 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 448 451 448 451 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 640 641 640 641 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">9</sup>
###xml 1001 1004 1001 1004 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 1027 1030 1027 1030 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
###xml 1333 1334 1333 1334 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</sup>
###xml 1677 1681 1677 1681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000013-Jalkanen1">[34]</xref>
###xml 111 115 <span type="species:ncbi:10090">mice</span>
###xml 133 148 <span type="species:ncbi:10090">Transgenic mice</span>
###xml 405 409 <span type="species:ncbi:10090">mice</span>
###xml 452 467 <span type="species:ncbi:10090">transgenic mice</span>
###xml 489 493 <span type="species:ncbi:10090">mice</span>
###xml 665 680 <span type="species:ncbi:10090">transgenic mice</span>
###xml 851 855 <span type="species:ncbi:10090">mice</span>
###xml 1179 1184 <span type="species:ncbi:9606">human</span>
###xml 1196 1201 <span type="species:ncbi:10090">mouse</span>
###xml 1521 1525 <span type="species:ncbi:10090">Mice</span>
pFlox plasmid was digested with Sal I/Asc I and the resulting fragment was microinjected into the CD2F1 hybrid mice (Balb/C x DBA2). Transgenic mice were analyzed from tail genomic DNA by PCR using specific primers for hVEGF-A165 (5'-ccatgaactttctgctgtc-3' and 5'-tcgtgagattctgccctc-3') and an internal control gene (ApoB with primers 5'-attgccttagatagtgcc-3' and 5'-tttgctagatttacacgg-3'), F6 generation mice were used for the experiments. hVEGF-A165 transgenic mice (n = 31) and control mice without the transgene (n = 10) were injected via tail vein with recombinant E1-partial E3-deleted first generation serotype 5 Cre adenovirus (1x109 pfu). Another group of transgenic mice (n = 10) were also injected with saline and served as additional controls. A subgroup of animals were sacrificed 1 to 4 weeks after the gene transfer and the rest of the mice were sacrificed 6 to 18 months after the gene transfer. Diet and water were provided ad libitum. Blood samples were taken and circulating hVEGF-A165 and endogenous mVEGF-A164 levels were measured from tail vein plasma samples at various time points after the gene transfer with enzyme-linked immunoassays (R&D; Quantikine, human VEGF-A and mouse VEGF-A). Routine clinical chemistry assays for aspartyl aminotransferase (ASAT) and C-reactive protein (CRP) were done with EcolineR25 (Merck Diagnostica) and Quickread CRP (Orion Diagnostica kits). During gene transfers animals were anesthetized using s.c. fentanyl-fluanisone (3.15 and 10 mg/kg)/midazolam (5 mg/kg). Mice were sacrificed using carbon dioxide. The arterial tree was perfused with PBS. Tissues samples were collected for the analysis of transgene expression [34] and either post fixed for 2 h (4% paraformaldehyde) and embedded in paraffin or frozen in liquid nitrogen for RNA and protein analyses. All animal experiments were approved by the Animal Care and use Committee the University of Kuopio.
###end p 19
###begin title 20
MRI and ELISA cross-reaction test
###end title 20
###begin p 21
###xml 113 116 113 116 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 122 124 122 124 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">10</sup>
###xml 795 796 791 792 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1003 1004 999 1000 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 56 60 <span type="species:ncbi:10090">mice</span>
###xml 216 220 <span type="species:ncbi:9913">calf</span>
###xml 286 290 <span type="species:ncbi:10090">mice</span>
###xml 491 495 <span type="species:ncbi:10090">Mice</span>
Another group of transgenic (n = 8) and control (n = 4) mice were transduced by AdCre or Ad-Tie-Cre or Ad hVEGF-A165 (1x1010 pfu/ml) in a total volume of 100 microl distributed into the distal hind limb and into the calf of the left hind limb. Right hind limbs served as controls. Only mice which were transduced by AdCre were followed up with MRI, others were used to evaluate possible cross-reaction by ELISA. MRI was performed at 1, 4, 7, 14, 21, 28, and 42 days after the gene transfer. Mice were anesthetized and positioned with straight-tighten hind limbs inside a surface coil. MRI was performed at 9.4 T vertical Oxford magnet (Oxford Instruments, Eynsham, UK) interfaced to a SMIS console (Surrey Medical Imaging Systems, Guilford, UK). Fat saturation was used in all MRI experiments. T2-weighted imaging was performed using a spin echo sequence with two adiabatic refocusing pulses. Total echo time (TE) was 44 ms, repetition time (TR) 2000 ms, resolution 256x128, field-of-view (FOV) 22x22 mm2 with 4 averages.
###end p 21
###begin title 22
Immunohistochemistry
###end title 22
###begin p 23
###xml 874 878 870 874 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000013-Cursiefen1">[35]</xref>
###xml 1707 1711 1703 1707 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000013-Leppnen1">[26]</xref>
###xml 678 681 <span type="species:ncbi:10116">rat</span>
###xml 687 692 <span type="species:ncbi:10090">mouse</span>
###xml 778 784 <span type="species:ncbi:9986">rabbit</span>
###xml 790 795 <span type="species:ncbi:10090">mouse</span>
###xml 1219 1224 <span type="species:ncbi:9606">Human</span>
###xml 1244 1248 <span type="species:ncbi:9925">goat</span>
For immunohistochemical analysis, serial sections (6 microm) were cut and used for stainings. Sections were routinely stained with hematoxylin-eosin and in selected cases with Masson Trichrom, PAS, and Alizarin Red S method for calcium in order to analyze basic changes in different tissues. Tissue vascularization was assessed by immunostaining with CD34 antibody (HyCult biotechnology BV, clone MEC 14.7, dilution 1:20). Antigen was visualized by avidin-biotin-HRP system (Vectastain ABC kit, Vector Laboratories). Endogenous avidin-biotin activity in liver was blocked by avidin/biotin blocking kit (Avidin/biotin Blocking kit, Vector Laboratories). Additionally, anti-CD 31 rat anti-mouse monoclonal antibody (PECAM-1, BD Pharmingen, clone MEC13.3, 1:50) and LYVE-1 primary rabbit anti-mouse monoclonal antibody (dilution 1:1000) were used to assess the vascular system [35]. Both antigens were detected using tyramide signal amplification (TSA Biotin System, PerkinElmer). Hepatocellular proliferation was analyzed by immunostaining for proliferating cell nuclear antigen (PCNA, Neomarkers, clone PC 10, dilution 1:500). Antigen was detected using the DAKO ARK kit (DakoCytomation Denmark A/S, Glostrup, Denmark). Human VEGF-A (polyclonal goat, R&D Systems, 1:500) was detected using avidin-biotin-HRP system (Vectastain ABC kit, Vector Laboratories). The signal was visualized with DAB (Zymed, South San Francisco, CA) or True Blue (KPL, Maryland, USA) as a chromogen. ApoTaq kit was used to evaluate apoptosis in livers after the gene transfer. Number of capillaries and apoptosis in the liver sections was counted in five randomly selected fields at 200x magnification using Olympus AX70 microscope [26] (Olympus Optical, Japan) and AnalySIS software (Soft Imaging System).
###end p 23
###begin title 24
RT-PCR and protein extractions
###end title 24
###begin p 25
###xml 415 418 415 418 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 432 436 432 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000013-Bhardwaj1">[36]</xref>
###xml 521 531 521 522 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8482;</sc>
###xml 600 610 591 592 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8482;</sc>
Total RNA was isolated with TRIzol compound (Invitrogen). RNA was DNAse treated and digested before cDNA synthesis with Eco 130I, which cuts the DNA in the middle of the amplification area in order to get rid of possible genomic contamination. cDNA was synthesized from the total RNA with Superscript II (Invitrogen) using random primers. Amplification of the transgene was performed using inner primers for hVEGF-A165 as described [36]. Proteins were extracted with T-PER Tissue Protein extraction reagent including Halttrade mark protease inhibitors and total protein contents were assayed with BCAtrade mark Protein Assay kit (Pierce, USA).
###end p 25
###begin title 26
Statistical analysis
###end title 26
###begin p 27
All statistical analysis were done using modified t-test (SPSS 7.5, SPSS Inc). Data are expressed as mean+/-SD and value of P<0.05 was considered significant.
###end p 27
###begin p 28
Authors want to thank Mervi Nieminen, Anne Martikainen, Tiina Koponen, Sari Jarvelainen, Seija Sahrio and Tuula Reponen for technical assistance.
###end p 28
###begin title 29
References
###end title 29
###begin article-title 30
###xml 15 20 <span type="species:ncbi:9606">human</span>
Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor.
###end article-title 30
###begin article-title 31
Novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases.
###end article-title 31
###begin article-title 32
The biology of VEGF and its receptors.
###end article-title 32
###begin article-title 33
Gene transfer as a tool to induce therapeutic vascular growth.
###end article-title 33
###begin article-title 34
Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene.
###end article-title 34
###begin article-title 35
Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele.
###end article-title 35
###begin article-title 36
###xml 53 57 <span type="species:ncbi:10090">mice</span>
Vegf is required for growth and survival in neonatal mice.
###end article-title 36
###begin article-title 37
###xml 64 68 <span type="species:ncbi:10090">mice</span>
Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188.
###end article-title 37
###begin article-title 38
###xml 26 31 <span type="species:ncbi:9606">human</span>
Model for gene therapy of human hereditary lymphedema.
###end article-title 38
###begin article-title 39
Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins.
###end article-title 39
###begin article-title 40
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice lacking the vascular endothelial growth factor-B gene (Vegfb) have smaller hearts, dysfunctional coronary vasculature, and impaired recovery from cardiac ischemia.
###end article-title 40
###begin article-title 41
Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions.
###end article-title 41
###begin article-title 42
Vascular endothelial growth factor D is dispensable for development of the lymphatic system.
###end article-title 42
###begin article-title 43
Massive inborn angiogenesis in the brain scarcely raises cerebral blood flow.
###end article-title 43
###begin article-title 44
###xml 96 111 <span type="species:ncbi:10090">transgenic mice</span>
Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice
###end article-title 44
###begin article-title 45
VEGF enhances pulmonary vasculogenesis and disrupts lung morphogenesis in vivo.
###end article-title 45
###begin article-title 46
###xml 0 15 <span type="species:ncbi:10090">Transgenic mice</span>
Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization
###end article-title 46
###begin article-title 47
Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy.
###end article-title 47
###begin article-title 48
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice overexpressing placenta growth factor exhibit increased vascularization and vessel permeability.
###end article-title 48
###begin article-title 49
###xml 43 58 <span type="species:ncbi:10090">transgenic mice</span>
Hyperplasia of lymphatic vessels in VEGF-C transgenic mice.
###end article-title 49
###begin article-title 50
###xml 100 115 <span type="species:ncbi:10090">transgenic mice</span>
Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice.
###end article-title 50
###begin article-title 51
Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis.
###end article-title 51
###begin article-title 52
###xml 58 66 <span type="species:ncbi:9606">patients</span>
Adenovirus-mediated gene transfer to lower limb artery of patients with chronic critical leg ischemia.
###end article-title 52
###begin article-title 53
###xml 36 41 <span type="species:ncbi:9606">human</span>
Beta-galactosidase gene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses.
###end article-title 53
###begin article-title 54
Site-specific recombinases: tools for genome engineering.
###end article-title 54
###begin article-title 55
###xml 142 146 <span type="species:ncbi:10090">mice</span>
Gene transfers of VEGF-A, VEGF-B, VEGF-C and VEGF-D have no effects on atherosclerosis in hypercholesterolemic LDL-receptor/ApoB48- deficient mice.
###end article-title 55
###begin article-title 56
Biodistribution of adenoviral vector to nontarget tissues after local in vivo gene transfer to arterial wall using intravascular and periadventitial gene delivery methods.
###end article-title 56
###begin article-title 57
Cardiovascular gene therapy.
###end article-title 57
###begin article-title 58
###xml 50 54 <span type="species:ncbi:10090">mice</span>
Conditional and indusible transgene expression in mice through combinatorial use of cre-mediated recombination and tetracycline induction.
###end article-title 58
###begin article-title 59
Angiogenesis-independent endothelial protection of liver: role of VEGFR-1.
###end article-title 59
###begin article-title 60
Adenovirus-mediated VEGF-A gene transfer induces bone formation in vivo.
###end article-title 60
###begin article-title 61
###xml 88 92 <span type="species:ncbi:10090">mice</span>
Spontaneous hepatocellular neoplasms and hepatic hemangiosarcomas in several strains of mice.
###end article-title 61
###begin article-title 62
###xml 63 78 <span type="species:ncbi:10090">transgenic mice</span>
Targeted oncogene activation by site-specific recombination in transgenic mice.
###end article-title 62
###begin article-title 63
###xml 54 59 <span type="species:ncbi:9606">human</span>
###xml 124 128 <span type="species:ncbi:10090">mice</span>
Adenovirus-mediated gene transfer of a secreted decoy human macrophage scavenger receptor (SR-AI) in LDL receptor knock-out mice.
###end article-title 63
###begin article-title 64
###xml 34 39 <span type="species:ncbi:9606">human</span>
Lymphatic vessels in vascularized human corneas: immunohistochemical investigation using LYVE-1 and podoplanin.
###end article-title 64
###begin article-title 65
Angiogenic Responses of Vascular Endothelial Growth Factors in Periadventitial Tissue.
###end article-title 65
###begin title 66
Figures and Tables
###end title 66
###begin title 67
###xml 40 43 40 43 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 162 165 162 165 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 256 259 256 259 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 435 438 432 435 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 149 154 <span type="species:ncbi:9606">human</span>
###xml 267 270 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 283 290 <span type="species:ncbi:9031">chicken</span>
###xml 423 428 <span type="species:ncbi:9606">human</span>
###xml 450 456 <span type="species:ncbi:9986">rabbit</span>
Shematic representation of pFlox hVEGF-A165 cassette, where VEGF expression is activated by Cre-mediated excision of STOP cassette and expression of human hVEGF-A165 in vitro after AdCre mediated transduction of NIH-3T3 cells with plasmid loxP-STOP-hVEGF-A165. CAG = CMV-IE enhancer+chicken beta-actin promoter; triangle = loxP, a 34 bp long recombination sequence; STOP = DNA element to prevent VEGF expression; hVEGF-A = human VEGF-A165 cDNA; pA = rabbit beta-globin polyadenylation signal.
###end title 67
###begin title 68
###xml 80 85 <span type="species:ncbi:9606">human</span>
###xml 90 95 <span type="species:ncbi:10090">mouse</span>
Edema after AdCre mediated local gene transfer detected by MRI and results from human and mouse ELISA analyses after local GT. Discrete edema (white areas pointed with arrows) is clearly visible between day 1 and day 7 under the skin in T2 weighted MRI images in the transduced leg muscles, their fascias, and in the fat tissue within the transduced muscles.
###end title 68
###begin p 69
###xml 43 50 43 50 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s3">Methods</xref>
ELISA assays were done as described in the Methods.
###end p 69
###begin title 70
###xml 14 19 <span type="species:ncbi:9606">human</span>
###xml 24 29 <span type="species:ncbi:10090">mouse</span>
Expression of human and mouse VEGF-A after AdCre gene transfer in vivo.
###end title 70
###begin p 71
###xml 10 13 10 13 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
A. hVEGF-A165 ELISA from sera after AdCre gene transfer.
###end p 71
###begin p 72
###xml 41 45 <span type="species:ncbi:10090">mice</span>
B. ASAT values in transgenic and control mice after AdCre gene transfer.
###end p 72
###begin p 73
###xml 40 44 <span type="species:ncbi:10090">mice</span>
C. CRP values in transgenic and control mice after AdCre gene transfer.
###end p 73
###begin p 74
###xml 24 27 24 27 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
D. Expression of hVEGF-A165 mRNA using RT-PCR.
###end p 74
###begin p 75
Lanes; 1 = Aorta, 2 = pancreas, 3 = kidney, 4 = heart, 5 = spleen, 6 = liver, 7 = positive control and 8 = liver without RT (500 bp pointed with an arrow).
###end p 75
###begin p 76
###xml 41 44 41 44 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 78 93 <span type="species:ncbi:10090">transgenic mice</span>
<500 and >500 in B and C refer to hVEGF-A165 serum levels in two subgroups of transgenic mice.
###end p 76
###begin title 77
Short term histopathological changes in the liver four weeks after gene transfer.
###end title 77
###begin p 78
A. Increased number of capillaries showing branching and sprouting (CD 34 immunostaining).
###end p 78
###begin p 79
Insert: PCNA immunostaining in nuclei correlated positively with the degree of angiogenesis.
###end p 79
###begin p 80
B. Control liver only revealed weak positivity in hepatic vein branches (CD 34 immunostaining).
###end p 80
###begin p 81
C. Details of neovascularization in the liver: formation of glomeruloid bodies and enhanced sprouting and branching (pointed with arrows, CD 34 immunostaining).
###end p 81
###begin p 82
D. Vascularization and proliferation in livers after AdCre gene transfer.
###end p 82
###begin p 83
###xml 69 72 69 72 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 39 43 <span type="species:ncbi:10090">mice</span>
ELISA values refer to two subgroups of mice with low and high hVEGF-A165 levels in serum.
###end p 83
###begin p 84
###xml 67 68 59 60 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 84 85 76 77 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
Bar: A insert, C-50 microm; B-100 microm. GT: gene transfer, cap/mm2: capillaries/mm2, NF: not found, * p<0,05.
###end p 84
###begin title 85
###xml 63 66 63 66 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
Long-term histopathological changes after activation of hVEGF-A165 expression.
###end title 85
###begin p 86
A. Liver: Dilated hepatic vein branches and mild dilatation of the sinuses (marked with *) (Haematoxylin-eosin).
###end p 86
###begin p 87
B. Liver: focal basophilic hyperplasia consisting of fat-filled hepatocytes (pointed with arrows), (Haematoxylin-eosin).
###end p 87
###begin p 88
C. Heart: epicardial calcification in ventricular myocardium (pointed with an arrow), (Haematoxylin-eosin, insert Alizarin RedS staining specific for calcium).
###end p 88
###begin p 89
D. Control heart. (Haematoxylin-eosin).
###end p 89
###begin p 90
E. Heart: ventricular myocardium revealed discrete edema and dilatation of subepicardial vessels (CD 31 immunostaining).
###end p 90
###begin p 91
###xml 3 7 <span type="species:ncbi:185716">Tuba</span>
F. Tuba uterina revealed high vascularization and focally dilated venules and arterioles (pointed with arrows), (CD 31 immunostaining).
###end p 91
###begin p 92
G. Pancreas with focally increased vasculature (Haematoxylin-eosin).
###end p 92
###begin p 93
H. Control pancreas. (Haematoxylin-eosin).
###end p 93
###begin p 94
I. Testes with increased and dilated vasculature (pointed with arrows), (CD 31 immunostaining).
###end p 94
###begin p 95
J. Control testes. (CD 31 immunostaining). Bar: A, B, C, D, I,J - 200 microm, G, H, E- 100 microm, F- 500 microm.
###end p 95
###begin title 96
###xml 57 60 57 60 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
Major changes after 16-months after activation of hVEGF-A165 expression.
###end title 96
###begin p 97
A. Liver: Encapsulated hepatocellular carcinoma was highly necrotic and focally calcified (Haematoxylin-eosin).
###end p 97
###begin p 98
B. Lung: Papillary adenocarcinoma. (Haematoxylin-eosin).
###end p 98
###begin p 99
C. Macroscopical changes in liver (box shows the area of the microscopical sections in F-H).
###end p 99
###begin p 100
D. Macroscopical changes in spleen, control spleen on the left (microscopical sections in I-K).
###end p 100
###begin p 101
E. Macroscopical changes in paratubarian area (microscopical sections in L-N).
###end p 101
###begin p 102
F. Cavernous hemangioma featuring focal hyalinization.
###end p 102
###begin p 103
G. The same tumor mass area with higher magnification (haematoxylin-eosin).
###end p 103
###begin p 104
###xml 21 24 21 24 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
H. Weak focal hVEGF-A165 immunoreactivity was present in the same area (True Blue as a chromogen), arrows indicate positive cells.
###end p 104
###begin p 105
I-K. Fibrous scars formed by collagenous and elastic fibres surrounded by dilated cystic spaces, focally filled with blood and revealing inconsistently CD34 positive lining.
###end p 105
###begin p 106
I. Hematoxylin-eosin. (an arrow points to an area shown in K)
###end p 106
###begin p 107
J. CD34 immunostaining.
###end p 107
###begin p 108
K. The same area as in I with higher magnification (stained with Masson Trichrom).
###end p 108
###begin p 109
Asterix in I and J indicate the same area.
###end p 109
###begin p 110
###xml 268 271 268 271 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 309 312 309 312 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
L. Cystically dilated paratubarian spaces with signs of old haemorrhage and thrombus formation (marked with *), an open circle points to an area which was highly vascularized as shown in M. (CD31 immunostaining) and a box indicates an area which revealed focal hVEGF-A165 immunopositivity shown in N. (hVEGF-A165 immunostaining).
###end p 110
###begin p 111
###xml 3 4 3 4 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">:</bold>
Bar: F, I, J - 500 microm, G, H, K - 100 microm, A, B, M, N - 200 microm L - 1000 microm.
###end p 111
###begin title 112
###xml 3 8 <span type="species:ncbi:9606">Human</span>
###xml 13 18 <span type="species:ncbi:10090">mouse</span>
A. Human and mouse VEGF-A ELISAs (pmol/mg) from tissue samples after systemic AdCre gene transfer (mean+/-SD)
###end title 112
###begin p 113
GT:gene transfer
###end p 113
###begin title 114
B. Summary of morphological changes in tissues after activation of hVEGF-A165 expression.
###end title 114
###begin p 115
GT:gene transfer, NF: not found
###end p 115
###begin p 116
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 116
###begin p 117
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was supported by grants from Sigrid Juselius Foundation, Finnish Foundation for Cardiovascular Research, Finnish Academy and European Union (Lymphangiogenenomics LSHG-CT-2004-503573) and European Vascular Genomics Network (EVGN, LSHM-CT-2003-503254).
###end p 117

